从2013年到2025年使用FDA不良事件报告系统 (FAERS) 数据库对与卡巴因相关的药监测分析
1Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada.
The Journal of antimicrobial chemotherapy
|February 20, 2026
概括
梅罗烯姆在卡巴烯姆中表现出最广泛的严重血液毒性,包括骨髓衰竭和农细胞瘤. 在这项药监测研究中,多里因没有显示出血液学安全信号.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 传染性疾病 传染性疾病
背景情况:
- 碳胺抗生素对于治疗多抗药性感染至关重要.
- 碳烯的血液学安全性比较资料尚未得到充分证实.
- 这项研究解决了与卡巴因相关的血液学不良事件的特征化需求.
研究的目的:
- 系统地评估和比较四种卡巴胺抗生素的血液学安全概况:美罗胺,埃尔塔胺,伊米胺和多里胺.
- 为了确定与每个卡巴因相关的特定血液学不良事件.
- 根据差异性安全配置文件,为临床选择卡巴胺提供信息.
主要方法:
- 从2013年1月到2025年7月,对FDA不良事件报告系统 (FAERS) 数据库的分析.
- 使用不成比例分析报告赔率比率 (ROR) 和95%置信区间.
- 专注于16个不同的血液学不良事件.
主要成果:
- 梅罗因在15种血液学不良事件中显示出显著信号,包括血栓塞动症,埃索诺菲利亚,骨髓衰竭,农核细胞症和泛细胞衰竭.
- 伊米内姆和埃尔塔内姆均显示了9个事件的信号,其中包括血小板缺血,埃索诺菲利亚,白血病和中性质缺血等显著事件.
- 没有为doripenem发现血液学不良事件报告.
结论:
- 在carbapenems中,血液学安全概况存在显著差异.
- 梅罗胺具有最广泛的严重血液毒性谱.
- 不同的安全性概况在选择碳烯时需要考虑,特别是对于具有先前血液病症的患者.
更多相关视频
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
27.8K
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
13.5K
相关概念视频
01:19Pharmacovigilance
1.8K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.8K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
01:26Pharmaceutical Poisoning: Potential Scenarios
22
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
22
01:29Therapeutic Drug Monitoring: Affecting Factors
266
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
266
01:26FDA Approved Drugs: Changes to Approved Drugs
289
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
289
01:12Analysis of Population Pharmacokinetic Data
830
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
830